Curasight A/S announced that it has entered into an exclusive global license and collaboration agreement with Curium Inc. for the development and commercialization of uTRACE for use in prostate cancer. Under the terms of the agreement, Curasight will develop its proprietary uTRACE technology for use in prostate cancer until regulatory approval is granted in the EU and USA. Curium will have responsibility for the commercial manufacture of uTRACE and world-wide commercialization.

Curium is eligible to receive up to USD 70 mn in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization. Curasight aims to position uTRACE as a first-in-class PET tracer that can serve as an alternative or supplement to traditional biopsies for the evaluation of patients with prostate cancer in active surveillance. Curasight recently received feedback from the US Food and Drug Administration (FDA) in a pre-IND meeting about the development plan for the [64]Cu-labeled version of uTRACE for use In prostate cancer.

The uTRACE platform is part of Curasight uPAR theranostic solution, made up of its uTRACE diagnostic technology and its uTREAT targeted treatment technology. By visualizing the cancer in an enhanced and intelligent way, the uTRACE platform aims to provide a more accurate diagnosis in certain types of cancer including prostate cancer, which can support a personalized treatment solution for each patient. The technology has been tested in multiple Phase 2 clinical trials.

Curium will keep all rights to develop and commercialize uTRACE in indications outside prostate cancer.